Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center

Cell Transplant. 2020 Jan-Dec:29:963689720950641. doi: 10.1177/0963689720950641.

Abstract

Stem cell transplantation remains the curative option for many patients with hematological malignancies. The long-term effects of these treatments on the patients and their immune systems have been extensively investigated, but there remains a paucity of data regarding autoimmune manifestations post-transplant, although these effects are well recognized.Herein we present the clinical picture and therapeutic approach in three patients (cases 1-3), with varied presentations of autoimmune disease post-transplant. Case 1 exhibited autoimmune hemolytic anemia and other autoimmune manifestations (serositis, thyroiditis), that were probably linked to graft versus relapsed leukemia effect. Cases 2 and 3 had pure red white cell aplasia and pure red cell aplasia, respectively, which were associated with hyperglobulinemia and a clonal T cell expansion.

Keywords: autoimmune disease; bone marrow transplant; graft versus host disease; hematopoietic stem cells; t cells.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alemtuzumab / adverse effects*
  • Autoimmune Diseases / etiology*
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Transplantation, Homologous

Substances

  • Alemtuzumab